JOHNSON KRISTINA M 4
4 · Infleqtion, Inc. · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
Infleqtion (INFQ) Director Kristina M. Johnson Exercises Options, Sells Shares
What Happened
- Kristina M. Johnson, a director of Infleqtion, reported multiple transactions on May 28, 2026: she exercised/options-converted 30,000 shares at $0.90 (cost $27,000) and another 30,000-share derivative conversion shown at $0.00, and she sold a total of 50,000 shares in open-market transactions (20,000 shares at a weighted average $18.00 = $360,000; 30,000 shares at a weighted average $16.45 = $493,500). The two sales together generated approximately $853,500 in proceeds. Sales are typically routine disposition transactions; the filing shows both exercises/conversions and sales on the same date but does not state whether the sold shares were the newly exercised shares.
Key Details
- Transaction date: May 28, 2026; Form 4 filed June 1, 2026 (timely).
- Sales: 20,000 shares at weighted avg $18.00 (prices ranged $17.85–$18.05 per F1) = $360,000; 30,000 shares at weighted avg $16.45 (prices ranged $16.45–$16.47 per F3) = $493,500.
- Exercises/Conversions: 30,000 shares acquired at $0.90 ($27,000); 30,000-share derivative conversion reported at $0.00 (disposition recorded as $0).
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
- Notable footnotes: F1/F3 explain weighted-average sale price ranges; F2 notes some shares are held by Catalyzer Ventures, LP Fund I (Dr. Johnson is a general partner and disclaims beneficial ownership except for her pecuniary interest); F4 describes a monthly vesting schedule (1/36 monthly beginning June 1, 2024) for certain option shares.
- No 10b5-1 plan, tax-withholding, or late-filing indication included in the excerpt.
Context
- The filing shows option exercise/conversion entries (code M) and open-market sales (code S) on the same day. That can indicate a simultaneous exercise-and-sell (cashless) pattern, but the Form 4 does not explicitly state whether sold shares were the newly exercised shares or pre-existing holdings—so avoid assuming the exact flow of shares.
- For retail investors: purchases (acquisitions) generally signal a clearer bullish personal view; here the only cash outlay reported is the $27,000 exercise. The larger activity reported is sales totaling roughly $853,500, which are often routine or liquidity-driven and do not by themselves indicate company performance.
Insider Transaction Report
Form 4
Infleqtion, Inc.INFQ
JOHNSON KRISTINA M
Director
Transactions
- Sale
Common Stock
[F1][F2]2026-05-28$18.00/sh−20,000$360,000→ 13,120 total(indirect: See footnote) - Exercise/Conversion
Common Stock
2026-05-28$0.90/sh+30,000$27,000→ 30,000 total - Sale
Common Stock
[F3]2026-05-28$16.45/sh−30,000$493,500→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
[F4]2026-05-28−30,000→ 343,458 totalExercise: $0.90Exp: 2034-06-05→ Common Stock (30,000 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.85 to $18.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]Held directly by Catalyzer Ventures, LP Fund I ("Catalyzer"). Dr. Johnson is a general partner of Catalyzer. Dr. Johnson disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.45 to $16.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The shares vest on a monthly basis beginning on June 1, 2024 with respect to 1/36 of the total number of shares until such time as the option is 100% vested, subject to the continuous service of the Reporting Person as of each such date.
Signature
/s/ Jason D. Hall, Attorney-in-Fact|2026-06-01